A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

NCT04603833 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

DRUG: SHR3680+Docetaxel
DRUG: SHR3680
DRUG: Docetaxel

Sponsor

Jiangsu HengRui Medicine Co., Ltd.